These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 16730719)
21. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143 [TBL] [Abstract][Full Text] [Related]
22. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341 [TBL] [Abstract][Full Text] [Related]
23. Role of obesity and adiposity in polycystic ovary syndrome. Diamanti-Kandarakis E Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S8-13; discussion S31-2. PubMed ID: 17968437 [TBL] [Abstract][Full Text] [Related]
24. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679 [TBL] [Abstract][Full Text] [Related]
25. Glucose intolerance in Japanese patients with polycystic ovary syndrome. Kurioka H; Takahashi K; Miyazaki K Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071 [TBL] [Abstract][Full Text] [Related]
26. [Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome]. Yang XF; Ren FR; Guo SP Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):261-3. PubMed ID: 16759463 [TBL] [Abstract][Full Text] [Related]
27. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808 [TBL] [Abstract][Full Text] [Related]
28. Polycystic ovary syndrome in obese adolescents. Stanley T; Misra M Curr Opin Endocrinol Diabetes Obes; 2008 Feb; 15(1):30-6. PubMed ID: 18185060 [TBL] [Abstract][Full Text] [Related]
29. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese. Syvertsen C; Halse J; Høivik HO; Gaullier JM; Nurminiemi M; Kristiansen K; Einerhand A; O'Shea M; Gudmundsen O Int J Obes (Lond); 2007 Jul; 31(7):1148-54. PubMed ID: 17031391 [TBL] [Abstract][Full Text] [Related]
30. Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women. Amato P; Morales AJ; Yen SS J Gerontol A Biol Sci Med Sci; 2000 May; 55(5):M260-3. PubMed ID: 10819315 [TBL] [Abstract][Full Text] [Related]
31. Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Kato I; Vogelman JH; Dilman V; Karkoszka J; Frenkel K; Durr NP; Orentreich N; Toniolo P Eur J Epidemiol; 1998 Sep; 14(6):621-6. PubMed ID: 9794131 [TBL] [Abstract][Full Text] [Related]
32. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin. Guido M; Romualdi D; De Marinis L; Porcelli T; Giuliani M; Costantini B; Lanzone A Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431 [TBL] [Abstract][Full Text] [Related]
33. [Hyperinsulinism and insulin resistance diagnosed by oral and intravenous glucose loading and by the tolbutamide test in polycystic ovary syndrome]. Cotrozzi G; Matteini M; Relli P; Lazzari T Recenti Prog Med; 1983 Mar; 74(3):289-97. PubMed ID: 6612073 [No Abstract] [Full Text] [Related]
34. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases]. Hu WH; Qiao J; Li MZ Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837 [TBL] [Abstract][Full Text] [Related]
35. Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Practice Committee of American Society for Reproductive Medicine Fertil Steril; 2008 Nov; 90(5 Suppl):S69-73. PubMed ID: 19007650 [TBL] [Abstract][Full Text] [Related]
36. The management of insulin resistance in polycystic ovary syndrome. Teede HJ; Hutchison SK; Zoungas S Trends Endocrinol Metab; 2007 Sep; 18(7):273-9. PubMed ID: 17698366 [TBL] [Abstract][Full Text] [Related]
37. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Pasquali R; Gambineri A Expert Opin Ther Targets; 2009 Oct; 13(10):1205-26. PubMed ID: 19650762 [TBL] [Abstract][Full Text] [Related]
38. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Diamanti-Kandarakis E; Economou FN; Livadas S; Tantalaki E; Piperi C; Papavassiliou AG; Panidis D Kidney Blood Press Res; 2009; 32(1):24-31. PubMed ID: 19212122 [TBL] [Abstract][Full Text] [Related]
39. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome. Georgopoulos NA; Katsikis I; Florakis D; Panidis D; Kandarakis ED Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719 [No Abstract] [Full Text] [Related]
40. Insulin-sensitizing agents in women with polycystic ovary syndrome. Pasquali R; Gambineri A Fertil Steril; 2006 Jul; 86 Suppl 1():S28-9. PubMed ID: 16798283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]